This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.

Advertisement Advertisement Advertisement Advertisement
Text Version  RSS  Subscribe  Unsubscribe  Archive  Media Kit November 14, 2014
Home    About AST    Education    Meetings & Events    Public Policy    Contact Us  



Nominations for AST Achievement Awards due Monday, Nov. 17
The deadline to submit your nominations for the 2015 AST Achievement Awards is this Monday, Nov. 17. The AST sponsors a variety of achievement awards according to faculty rank in recognition of our members’ achievements and contributions to the field of transplantation. AST members are encouraged to nominate deserving candidates for consideration. For complete information on awards eligibility criteria, application requirements, the review process, and to submit a nomination, please click here.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Vaccine updates in SOT – Free webinar on Nov. 18
Join Dr. Deepali Kumar and Dr. Lara Danziger-Isakov at 2 p.m. EST on Nov. 18 to learn the current recommendations for vaccination and the latest innovative research. Register today at – it's free for AST members and only $25 for non-members.

Learning objectives:
  • Explore current pre- and post-transplant vaccination recommendations for pediatric and adult transplant candidates/recipients.
  • Appraise recent vaccination studies in transplantation with a focus on live-vaccines and more recently approved vaccinations.
  • Identify new opportunities for vaccination in transplantation that are emerging.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Deeply discounted early registration rates end soon
The Cutting Edge of Transplantation
Immunity and Inflammation: Engineering Cell, Gene, and Drug Therapies

Feb. 5-7, 2015
Sheraton Wild Horse Pass – Chandler, Arizona

Time is running out to take advantage of deep discounts on registration for CEOT. Register by Nov. 30 to enjoy heavily discounted rates. These early registration rates are the lowest rates that will be available for this meeting. Make plans to attend this high-energy, intimate meeting where expert clinicians, leading diagnosticians, and world-class scientists will address the field’s cutting-edge challenges together with an engaged audience. This year's CEOT will feature talks on:
  • Tregs: What is the Promise of Cell Therapy Today?
  • Promising New Drugs in Other Fields: Best in Rheumatology, Inflammatory Bowel Disease & Cancer Immunology
  • Adding Value: The Approach to Repurposing Drugs
  • Novel Approaches to Modifying the Genome
  • Genetic Manipulation to “Supercharge” T Cells
  • Novel Therapeutic Strategies for Regenerative Medicine
  • Differentiation of Stem Cells in 3D
Click here to register for CEOT 2015 and take advantage of early registration discounted rates! Or, learn more about this engaging meeting and view the preliminary program here.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Raptor's mission is to develop and commercialize life-altering therapeutics that treat rare, debilitating, and often fatal diseases.
Advertise here!

To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.


FDA approves Gilead's hep C drug Harvoni (ledipasvir/sofosbuvir)
The U.S. Food and Drug Administration has approved Gilead Sciences' hotly anticipated new hepatitis C virus (HCV) therapy Harvoni (ledipasvir/sofosbuvir). Boasting high cure rates, this first-ever fixed-dose combination tablet is indicated for the treatment of people with genotype 1 of the virus, who make up 70 percent of the HCV-positive U.S. population.

Related: Gilead hepatitis C drug highly effective in cirrhosis patients (Reuters)

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

A complete treatment of adult living donor liver transplantation: A review of surgical technique and current challenges to expand indication of patients
American Journal of Transplantation
The growing disparity between the number of liver transplant candidates and the supply of deceased donor organs has motivated the development of living donor liver transplantation (LDLT). Over the last two decades, the operation has been markedly improved by innovations rendering modern results comparable with those of deceased donor liver transplantation (DDLT). However, there remains room for further innovation, particularly in adult living donor liver transplantation (ALDLT).
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

An interferon-free antiviral regimen for HCV after liver transplantation
The New England Journal of Medicine
Hepatitis C virus (HCV) infection is the leading indication for liver transplantation worldwide, and interferon-containing regimens are associated with low response rates owing to treatment-limiting toxic effects in immunosuppressed liver-transplant recipients. We evaluated the interferon-free regimen of the NS5A inhibitor ombitasvir coformulated with the ritonavir-boosted protease inhibitor ABT-450 (ABT-450/r), the nonnucleoside NS5B polymerase inhibitor dasabuvir, and ribavirin in liver-transplant recipients with recurrent HCV genotype 1 infection.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  UCLA Immunogenetics Center

The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE

Donor-specific antibodies in allograft recipients: Etiology, impact, and therapeutic approaches
Current Opinion in Organ Transplantation
Kidney transplantation remains the treatment of choice for patients with end-stage renal failure. However, despite significant advancements in detection of donor-specific human leukocyte antigen antibodies, improved immunosuppression and patient management, the durability of this life-saving therapy has not improved. This results in increased morbidity and mortality as well as increased cost to the healthcare system.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Actual and perceived knowledge of kidney transplantation and the pursuit of a live donor
Live donor kidney transplantation (LDKT) remains underutilized, partly resulting from the challenges many patients face in asking someone to donate. Actual and perceived kidney transplantation (KT) knowledge are potentially modifiable factors that may influence this process. Therefore, we sought to explore the relationships between these constructs and the pursuit of LDKT.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Reframing the impact of combined heart-liver allocation on liver transplant wait-list candidates
Liver Transplantation
Simultaneous heart-liver (H-L) transplantation, although rare, has become more common in the United States. When the primary organ is a heart or liver, patients receiving an offer for the primary organ automatically receive the second, nonprimary organ from that donor. This policy raises issues of equity, such as whether liver transplantation alone candidates bypassed by H-L recipients are disadvantaged. No prior published analyses have addressed this issue, and few methods have been developed as means of measuring the impact of such allocation policies.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Comparing living donor and deceased donor liver transplantation: A matched national analysis from 2007 to 2012
Liver Transplantation
A complete evaluation of living donor liver transplantation (LDLT) in the United States has been difficult because of the persistent low volume and the lack of adequate comparisons with deceased donor liver transplantation (DDLT). Recent reports have suggested outcomes equivalent to those for DDLT, but these studies did not adjust for differences in recipient selection. From a linkage between the University HealthSystem Consortium and Scientific Registry of Transplant Recipients databases, we identified 14,282 patients at 62 centers who underwent DDLT from 2007 to 2012 and 715 patients at 35 centers who underwent LDLT during the same period.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Missed last week's issue? See which articles your colleagues read most.

    Early corticosteroid avoidance in kidney transplant recipients receiving ATG-F induction: 5-year actual results of a prospective and randomized study (American Journal of Transplantation)
Preparing for the inevitable: The death of a living liver donor (Liver Transplantation)
Impact of donor mismatches at individual HLA-A, -B, -C, -DR, and -DQ loci on the development of HLA-specific antibodies in patients listed for repeat renal transplantation (Kidney International)
Risk factors for early and late biliary complications in pediatric liver transplantation (Pediatric Transplantation)

Don't be left behind. Click here to see what else you missed.

High early cardiovascular mortality after liver transplantation
Liver Transplantation
Cardiovascular disease (CVD) contributes to excessive long-term mortality after liver transplantation (LT); however, little is known about early postoperative CVD mortality in the current era. In addition, there is no model for predicting early postoperative CVD mortality across centers. We analyzed adult recipients of primary LT in the Organ Procurement and Transplantation Network (OPTN) database between February 2002 and December 2012 to assess the prevalence and predictors of early (30-day) CVD mortality, which was defined as death from arrhythmia, heart failure, myocardial infarction, cardiac arrest, thromboembolism, and/or stroke.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Acute rejection in vascularized composite allotransplantation
Current Opinion in Organ Transplantation
Acute rejection is the most common complication after vascularized composite allotransplantation (VCA). This review provides a state-of-the-art analysis of prevention, diagnosis and treatment of acute rejection episodes and highlights recent findings with the potential to improve patient care and enhance understanding of the underlying biologic processes.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Julie Bernhard, Executive Editor, 469.420.2647  
Contribute news

This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Nov. 7, 2014
Oct. 31, 2014
Oct. 24, 2014
Oct. 17, 2014

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063